Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.

BACKGROUND Voriconazole shows a considerable interpatient variation of serum concentrations. METHODS AND RESULT In an analysis of 28 treatment courses, 6 patients presented with neurological adverse events (hallucination, encephalopathy, and visual disturbance). The hazard ratio per 0.1 mg/mL voriconazole serum level (sVL) increase was 2.27 (95% CI: 1.45-3.56, p <0.001). There was no correlation between sVL and creatinine (r = 0.12, p = 0.114), ALT (r = -0.14, p = 0.072), AST (r = 0.003, p = 0.964), alkaline phosphatase (r = 0.03, p = 0.723). CONCLUSIONS Our findings demonstrate that elevated sVL is associated with neurological adverse events, and measurement of its serum concentration could improve voriconazole treatment and safety.

[1]  N. Wood,et al.  Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.

[2]  J. Mehta,et al.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.

[3]  B. Keevil,et al.  Adverse reactions to voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Agrawal,et al.  Voriconazole-Induced Musical Hallucinations , 2004, Infection.

[5]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  C. A. Kauffman,et al.  Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Margaret M Pearson,et al.  Voriconazole: A New Triazole Antifungal Agent , 2003, The Annals of pharmacotherapy.

[8]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[9]  Thomas J Walsh,et al.  Antifungal chemotherapy: advances and perspectives. , 2002, Swiss medical weekly.

[10]  M. Ghannoum,et al.  Voriconazole -- better chances for patients with invasive mycoses. , 2002, European journal of medical research.

[11]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[13]  Laishun Chen,et al.  Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[14]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[15]  L. Pickle,et al.  The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study , 1995, Clinical pharmacology and therapeutics.

[16]  D. Schaer,et al.  110 Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring , 2006 .

[17]  N. Karandreas,et al.  Painful peripheral neuropathy associated with voriconazole use. , 2005, Archives of neurology.

[18]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.